Definium Therapeutics Inc
Research Definium Therapeutics Inc (DFTX) on Bullrun: market cap USD 6.02B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerDFTX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 6.02B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 158.99M
- Free cash flow-USD 52.78M
Valuation Snapshot
latest market cap is USD 6.02B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 183.79M | -USD 131.56M | n/a | -2.06 | USD 257.84M | USD 40.58M | USD 332.33M |
| FY2024 | n/a | -USD 108.68M | n/a | n/a | -1.54 | USD 273.74M | USD 21.85M | USD 241.45M |
| FY2023 | n/a | -USD 95.73M | n/a | n/a | -2.44 | USD 99.70M | USD 14.13M | USD 78.13M |
| FY2022 | n/a | -USD 56.80M | n/a | n/a | -1.84 | USD 142.14M | n/a | USD 150.92M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 6.02B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.32B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 522.70M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 146.75M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 82.66M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 581.60M | n/a | n/a | n/a |
About Definium Therapeutics Inc
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Definium Therapeutics Inc's market cap?
Definium Therapeutics Inc's market capitalization is USD 6.02B.
What does Definium Therapeutics Inc do?
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026.